Building the biopharma company of the future

Developing New Categories of Medicine

Our goal is to improve and extend the lives of patients through the development of new categories of medicine

Exploring the Brain Immune Gut (BIG) Axis

Focused on the crosstalk and biological processes associated with the brain-immune-gut interface

Giving Life to Science

Our goal is to improve and extend the lives of patients

Moving Medicine Forward

Discovery Reinvented

Publications
Publications -2017-09-19
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Publications -2017-09-19
The Gut’s Clostridium Cocktail

Specific components of the microbiota—the microorganisms that normally colonize the body—can affect disease progression in mouse models of arthritis, central nervous system inflammation, diabetes, intestinal inflammation, and obesity.

Full Article
Publications -2017-06-01
Video game training enhances cognitive control in older adults

Cognitive controlis defined by a set of neural processes that allow us to interact with our complex environment in a goal-directed manner.

FULL ARTICLE

Press releases
2017-12-13
PureTech’s Vedanta Biosciences Granted Four New US Patents Expanding Coverage for Compositions and Methods of Use for Medicines Based on Microbiome-Derived Bacterial Consortia

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Vedanta Biosciences, an affiliate of PureTech Health, today announced that the United States Patent and Trademark Office (USPTO) has issued four new patents to Vedanta Biosciences, which broadly cover compositions of matter and methods of use for therapeutic products, including mixtures of bacterial strains and spore-forming fractions based on beneficial bacteria.

Continue

Press releases
2017-12-11
PureTech Health Affiliate resTORbio Adds Paul Fonteyne, CEO of Boehringer Ingelheim USA, to Board of Directors

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that resTORbio, an affiliate of PureTech Health, today announced that Paul Fonteyne, President and CEO of Boehringer Ingelheim USA, has joined the resTORbio board of directors as an independent director.

Continue

Press releases
2017-12-07
PureTech’s Microbiome Programme Advances into a Phase 1a/1b Clinical Trial

VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has received Orphan Drug Designation from the US FDA for C. difficile indication

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Vedanta Biosciences, an affiliate of PureTech Health, today announced the initiation of a Phase 1a/1b clinical trial of VE303, the Company’s lead, orally-administered, human microbiome-derived product candidate.

Continue